Pharmaceutical

AbbVie’s RINVOQ now indicated for paediatric arthritis in US

AbbVie's RINVOQ is now indicated for polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA) in paediatric patients.

Jun 6, 2024 - 04:00
AbbVie’s RINVOQ now indicated for paediatric arthritis in US
AbbVie's RINVOQ is now indicated for polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA) in paediatric patients.
Read the original article

Tags:

Previous Article

MDMA therapy wait goes on as FDA panel rejects Lykos’ PTSD treatment

Next Article

J&J seeks expanded approvals for paediatric HIV-1 therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia

NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia

Oct 8, 2024

Takeda set to build $764m manufacturing facility in Japan

Takeda set to build $764m manufacturing facility in Japan

Mar 25, 2023

STAT+: Pharmalittle: Amgen ends two lupus programs; Illumina sequencers have security vulnerability

STAT+: Pharmalittle: Amgen ends two lupus programs; Ill...

Apr 29, 2023